<p>RNS 编号：0268L Janus Henderson Investors2025 年 12 月 10 日</p>
<p>Ap27</p>
<p>表格 8.3</p>
<p>爱尔兰收购委员会</p>
<p>根据 1997 年爱尔兰收购委员会法第 8.3 条的规定，关于相关证券的开盘头寸披露/交易披露</p>
<p>规则，2022 年由持有 1% 或以上相关证券的人员披露</p>
<p>1. 关键信息</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露者全名</td>
<td>Janus Henderson Group plc</td>
</tr>
<tr>
<td>(b) 如果与 1(a) 不同，持有披露的利益和空头头寸的所有者或控制者<br/>提名或公司名义的命名是不够的。对于信托，必须命名受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>(c) 与本表格相关的要约方/被要约方的名称<br/>每个要约方/被要约方使用单独的表格</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(d) 如果是与要约方/被要约方相关的豁免基金经理，请说明并指定要约方/被要约方的身份（注 1）</td>
<td></td>
</tr>
<tr>
<td>(e) 持有头寸/进行交易的日期<br/>对于开盘头寸披露，请说明披露前的最新可行日期</td>
<td>2025 年 12 月 9 日</td>
</tr>
<tr>
<td>(f) 除上述 1(c) 的公司外，披露者是否还在对任何其他要约方进行披露？<br/>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<p>2. 利益和空头头寸</p>
<p>如果需要披露的要约方或被要约方在 1(c) 中提到的相关证券的多个类别中存在利益和空头头寸，请为每个额外的相关证券类别复制表 2。</p>
<p>Ap28</p>
<p>与披露相关的要约方或被要约方的相关证券的利益和空头头寸（如有）</p>
<p>（注 2）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别<br/>（注 3）</td>
<td>$0.01 普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>利益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券</td>
<td>3,635,795*</td>
<td>3.73%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 现金结算衍生品</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 股票结算衍生品（包括期权）和购买/出售协议</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计</td>
<td>3,635,795*</td>
<td>3.73%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>*Janus Henderson Group Plc 对包含在上述总数中的 66,461 股的投票决策没有裁量权。</p>
<p>所有利益和所有空头头寸都应披露。</p>
<p>包括认购新证券的权利和任何未平仓的股票结算衍生品头寸（包括交易期权）或购买或出售相关证券的协议的选项详细信息，应在补充表格 8 中提供。</p>
<p>3. 披露者的交易（如有）（注 4）</p>
<p>如果在 1(c) 中提到的要约方或被要约方的多个类别的相关证券中有交易，请为每个额外的相关证券类别复制表 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
<p>所有价格和其他货币金额的货币应予以说明。</p>
<p>(a) 购买和销售</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>€0.01 普通股</td>
</tr>
<tr>
<td>购买/销售</td>
<td>销售</td>
</tr>
<tr>
<td>证券数量</td>
<td>69</td>
</tr>
<tr>
<td>每单位价格<br/>（注 5）</td>
<td>USD 21.3250</td>
</tr>
</tbody>
</table>
<p>Ap29</p>
<p>(b) 现金结算衍生品交易</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如 CFD</li>
<li>交易性质，例如开立/平仓多头/空头头寸，增加/减少多头/空头头寸</li>
<li>参考证券数量（注 6）</li>
<li>每单位价格（注 5）</li>
</ul>
<p>(c) 股票结算衍生品交易（包括期权）</p>
<p>(i) 写入、出售、购买或变更</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>写入、购买、出售、变更等。</li>
<li>与期权相关的证券数量（注 6）</li>
<li>每单位行使价格</li>
<li>类型，例如美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付/收到的期权金额</li>
</ul>
<p>(ii) 行使</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>行使/已行使</li>
<li>证券数量</li>
<li>每单位行使价格（注 5）</li>
</ul>
<p>(d) 其他交易（包括新证券的交易）（注 3）</p>
<ul>
<li>相关证券类别</li>
<li>交易性质，例如认购、转换、行使</li>
<li>详细信息</li>
<li>每单位价格（如适用）（注 5）</li>
</ul>
<p>Ap30</p>
<p>4. 其他信息</p>
<p>(a) 赔偿和其他交易安排</p>
<ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使披露者与要约方或与要约方一致行动的任何人进行交易或避免交易。不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
<p>(b) 与期权或衍生品相关的协议、安排或理解</p>
<ul>
<li>披露者与任何其他人之间关于本表格中提到的任何期权下的相关证券的投票权的任何协议、安排或理解的完整详细信息，或与本表格中提到的任何衍生品的相关证券的投票权或未来的收购或处置相关的。如果没有，应说明。</li>
<li>无</li>
</ul>
<p>(c) 附件</p>
<ul>
<li>是否附有补充表格 8？</li>
<li>否</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 10 日</td>
</tr>
<tr>
<td>联系人姓名</td>
<td>John Baker</td>
</tr>
<tr>
<td>电话号码</td>
<td>+44 207 818 3064</td>
</tr>
</tbody>
</table>
<p>根据规则 8.3 的规定，公共披露必须向监管信息服务进行。</p>
<p>Ap31</p>
<p>关于表格 8.3 的说明</p>
<p>1. 请参见规则第 A 部分第 2.2 条中 “相关基金经理” 的定义。</p>
<p>2. 请参见规则第 A 部分第 2.5 条中 “相关证券的利益” 的定义，并参见规则第 B 部分第 8.6(a) 和 (b) 条。</p>
<p>3. 请参见规则第 A 部分第 2.1 条中 “相关证券” 的定义。</p>
<p>4. 请参见规则第 A 部分第 2.1 条中 “交易” 的定义。</p>
<p>5. 如果对证券价格变动的经济风险暴露有限，例如通过与差价合约相关的止损安排，则必须提供完整的细节。</p>
<p>6. 请参见规则第 2.5(d) 条。</p>
<p>7. 如果根据规则第 8 条披露的信息不正确，应在后续披露中尽快更正。该披露应明确说明其更正了之前披露的细节，识别被更正的披露，并提供足够的细节以便读者理解更正的性质。如有任何疑问，应咨询小组。</p>
<p>有关披露要求的完整细节，请参见规则第 8 条。如有疑问，请咨询小组。</p>
<p>这些说明中提到的 “规则” 是指 1997 年爱尔兰收购小组法案、2022 年收购规则。</p>
<p>此信息由伦敦证券交易所的新闻服务 RNS 提供。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动，并将此类分析以匿名方式与他人分享，作为我们商业服务的一部分。有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参见我们的隐私政策。结束 ITPMZMMZMGRGKZM</p>

Avadel制药

<p>Janus Henderson Investors 根据爱尔兰收购小组法第 8.3 条披露了他们在 Avadel Pharmaceuticals plc 的持股和空头头寸。他们持有 3,635,795 股普通股，占相关证券的 3.73%。该披露包括购买、销售和衍生交易的详细信息，没有任何赔偿或期权安排。该公告由 John Baker 于 2025 年 12 月 10 日发布</p>

<p>RNS Number : 0268L Janus Henderson Investors 10 December 2025</p>
<div class="lb-trans"><p>RNS 编号：0268L Janus Henderson Investors2025 年 12 月 10 日</p>
</div><p>Ap27</p>
<div class="lb-trans"><p>Ap27</p>
</div><p>FORM 8.3</p>
<div class="lb-trans"><p>表格 8.3</p>
</div><p>IRISH TAKEOVER PANEL</p>
<div class="lb-trans"><p>爱尔兰收购委员会</p>
</div><p>OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER</p>
<div class="lb-trans"><p>根据 1997 年爱尔兰收购委员会法第 8.3 条的规定，关于相关证券的开盘头寸披露/交易披露</p>
</div><p>RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE</p>
<div class="lb-trans"><p>规则，2022 年由持有 1% 或以上相关证券的人员披露</p>
</div><p>1. KEY INFORMATION</p>
<div class="lb-trans"><p>1. 关键信息</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Full name of discloser</td>
<td>Janus Henderson Group plc</td>
</tr>
<tr>
<td>(b) Owner or controller of interests and short positions disclosed, if different from 1(a)<br/>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</td>
<td></td>
</tr>
<tr>
<td>(c) Name of offeror/offeree in relation to whose relevant securities this form relates<br/>Use a separate form for each offeror/offeree</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)</td>
<td></td>
</tr>
<tr>
<td>(e) Date position held/dealing undertaken<br/>For an opening position disclosure, state the latest practicable date prior to the disclosure</td>
<td>09 December 2025</td>
</tr>
<tr>
<td>(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?<br/>If it is a cash offer or possible cash offer, state &#34;N/A&#34;</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露者全名</td>
<td>Janus Henderson Group plc</td>
</tr>
<tr>
<td>(b) 如果与 1(a) 不同，持有披露的利益和空头头寸的所有者或控制者<br/>提名或公司名义的命名是不够的。对于信托，必须命名受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>(c) 与本表格相关的要约方/被要约方的名称<br/>每个要约方/被要约方使用单独的表格</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>(d) 如果是与要约方/被要约方相关的豁免基金经理，请说明并指定要约方/被要约方的身份（注 1）</td>
<td></td>
</tr>
<tr>
<td>(e) 持有头寸/进行交易的日期<br/>对于开盘头寸披露，请说明披露前的最新可行日期</td>
<td>2025 年 12 月 9 日</td>
</tr>
<tr>
<td>(f) 除上述 1(c) 的公司外，披露者是否还在对任何其他要约方进行披露？<br/>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>2. INTERESTS AND SHORT POSITIONS</p>
<div class="lb-trans"><p>2. 利益和空头头寸</p>
</div><p>If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.</p>
<div class="lb-trans"><p>如果需要披露的要约方或被要约方在 1(c) 中提到的相关证券的多个类别中存在利益和空头头寸，请为每个额外的相关证券类别复制表 2。</p>
</div><p>Ap28</p>
<div class="lb-trans"><p>Ap28</p>
</div><p>Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)</p>
<div class="lb-trans"><p>与披露相关的要约方或被要约方的相关证券的利益和空头头寸（如有）</p>
</div><p>(Note 2)</p>
<div class="lb-trans"><p>（注 2）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security <br/>(Note 3)</td>
<td>$0.01 ordinary shares</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interests</td>
<td>Short positions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>%</td>
<td>Number</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) Relevant securities owned and/or controlled</td>
<td>3,635,795*</td>
<td>3.73%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) Cash-settled derivatives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) Stock-settled derivatives (including options) and agreements to purchase/ sell</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>3,635,795*</td>
<td>3.73%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别<br/>（注 3）</td>
<td>$0.01 普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>利益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券</td>
<td>3,635,795*</td>
<td>3.73%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 现金结算衍生品</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 股票结算衍生品（包括期权）和购买/出售协议</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计</td>
<td>3,635,795*</td>
<td>3.73%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>*Janus Henderson Group Plc does not have discretion regarding voting decisions in respect 66,461 shares that are included in the total above.</p>
<div class="lb-trans"><p>*Janus Henderson Group Plc 对包含在上述总数中的 66,461 股的投票决策没有裁量权。</p>
</div><p>All interests and all short positions should be disclosed.</p>
<div class="lb-trans"><p>所有利益和所有空头头寸都应披露。</p>
</div><p>Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.</p>
<div class="lb-trans"><p>包括认购新证券的权利和任何未平仓的股票结算衍生品头寸（包括交易期权）或购买或出售相关证券的协议的选项详细信息，应在补充表格 8 中提供。</p>
</div><p>3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)</p>
<div class="lb-trans"><p>3. 披露者的交易（如有）（注 4）</p>
</div><p>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</p>
<div class="lb-trans"><p>如果在 1(c) 中提到的要约方或被要约方的多个类别的相关证券中有交易，请为每个额外的相关证券类别复制表 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
</div><p>The currency of all prices and other monetary amounts should be stated.</p>
<div class="lb-trans"><p>所有价格和其他货币金额的货币应予以说明。</p>
</div><p>(a) Purchases and sales</p>
<div class="lb-trans"><p>(a) 购买和销售</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant<br/>security</td>
<td>€0.01 ordinary shares</td>
</tr>
<tr>
<td>Purchase/sale</td>
<td>Sale</td>
</tr>
<tr>
<td>Number of<br/>securities</td>
<td>69</td>
</tr>
<tr>
<td>Price per unit<br/>(Note 5)</td>
<td>USD 21.3250</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>€0.01 普通股</td>
</tr>
<tr>
<td>购买/销售</td>
<td>销售</td>
</tr>
<tr>
<td>证券数量</td>
<td>69</td>
</tr>
<tr>
<td>每单位价格<br/>（注 5）</td>
<td>USD 21.3250</td>
</tr>
</tbody>
</table>
</div><p>Ap29</p>
<div class="lb-trans"><p>Ap29</p>
</div><p>(b) Cash-settled derivative transactions</p>
<div class="lb-trans"><p>(b) 现金结算衍生品交易</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. CFD</li>
<li>Nature of dealing e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position</li>
<li>Number of reference securities (Note 6)</li>
<li>Price per unit (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如 CFD</li>
<li>交易性质，例如开立/平仓多头/空头头寸，增加/减少多头/空头头寸</li>
<li>参考证券数量（注 6）</li>
<li>每单位价格（注 5）</li>
</ul>
</div><p>(c) Stock-settled derivative transactions (including options)</p>
<div class="lb-trans"><p>(c) 股票结算衍生品交易（包括期权）</p>
</div><p>(i) Writing, selling, purchasing or varying</p>
<div class="lb-trans"><p>(i) 写入、出售、购买或变更</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Writing, purchasing, selling, varying etc.</li>
<li>Number of securities to which option relates (Note 6)</li>
<li>Exerciseprice per unit</li>
<li>Type e.g. American, Europeanetc.</li>
<li>Expiry date</li>
<li>Option moneypaid/ received per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>写入、购买、出售、变更等。</li>
<li>与期权相关的证券数量（注 6）</li>
<li>每单位行使价格</li>
<li>类型，例如美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付/收到的期权金额</li>
</ul>
</div><p>(ii) Exercise</p>
<div class="lb-trans"><p>(ii) 行使</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Exercising/ exercised against</li>
<li>Number of securities</li>
<li>Exercise price per unit (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>行使/已行使</li>
<li>证券数量</li>
<li>每单位行使价格（注 5）</li>
</ul>
</div><p>(d) Other dealings (including transactions in respect of new securities) (Note 3)</p>
<div class="lb-trans"><p>(d) 其他交易（包括新证券的交易）（注 3）</p>
</div><ul>
<li>Class of relevant security</li>
<li>Nature of dealing e.g. subscription, conversion, exercise</li>
<li>Details</li>
<li>Price per unit (if applicable) (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>交易性质，例如认购、转换、行使</li>
<li>详细信息</li>
<li>每单位价格（如适用）（注 5）</li>
</ul>
</div><p>Ap30</p>
<div class="lb-trans"><p>Ap30</p>
</div><p>4. OTHER INFORMATION</p>
<div class="lb-trans"><p>4. 其他信息</p>
</div><p>(a) Indemnity and other dealing arrangements</p>
<div class="lb-trans"><p>(a) 赔偿和其他交易安排</p>
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使披露者与要约方或与要约方一致行动的任何人进行交易或避免交易。不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div><p>(b) Agreements, arrangements or understandings relating to options or derivatives</p>
<div class="lb-trans"><p>(b) 与期权或衍生品相关的协议、安排或理解</p>
</div><ul>
<li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>披露者与任何其他人之间关于本表格中提到的任何期权下的相关证券的投票权的任何协议、安排或理解的完整详细信息，或与本表格中提到的任何衍生品的相关证券的投票权或未来的收购或处置相关的。如果没有，应说明。</li>
<li>无</li>
</ul>
</div><p>(c) Attachments</p>
<div class="lb-trans"><p>(c) 附件</p>
</div><ul>
<li>Is a Supplemental Form 8 attached?</li>
<li>No</li>
</ul>
<div class="lb-trans"><ul>
<li>是否附有补充表格 8？</li>
<li>否</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure</td>
<td>10 December 2025</td>
</tr>
<tr>
<td>Contact name</td>
<td>John Baker</td>
</tr>
<tr>
<td>Telephone number</td>
<td>+44 207 818 3064</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 10 日</td>
</tr>
<tr>
<td>联系人姓名</td>
<td>John Baker</td>
</tr>
<tr>
<td>电话号码</td>
<td>+44 207 818 3064</td>
</tr>
</tbody>
</table>
</div><p>Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.</p>
<div class="lb-trans"><p>根据规则 8.3 的规定，公共披露必须向监管信息服务进行。</p>
</div><p>Ap31</p>
<div class="lb-trans"><p>Ap31</p>
</div><p>NOTES ON FORM 8.3</p>
<div class="lb-trans"><p>关于表格 8.3 的说明</p>
</div><p>1. See the definition of &#34;connected fund manager&#34; in Rule 2.2 of Part A of the Rules.</p>
<div class="lb-trans"><p>1. 请参见规则第 A 部分第 2.2 条中 “相关基金经理” 的定义。</p>
</div><p>2. See the definition of &#34;interest in a relevant security&#34; in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.</p>
<div class="lb-trans"><p>2. 请参见规则第 A 部分第 2.5 条中 “相关证券的利益” 的定义，并参见规则第 B 部分第 8.6(a) 和 (b) 条。</p>
</div><p>3. See the definition of &#34;relevant securities&#34; in Rule 2.1 of Part A of the Rules.</p>
<div class="lb-trans"><p>3. 请参见规则第 A 部分第 2.1 条中 “相关证券” 的定义。</p>
</div><p>4. See the definition of &#34;dealing&#34; in Rule 2.1 of Part A of the Rules.</p>
<div class="lb-trans"><p>4. 请参见规则第 A 部分第 2.1 条中 “交易” 的定义。</p>
</div><p>5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.</p>
<div class="lb-trans"><p>5. 如果对证券价格变动的经济风险暴露有限，例如通过与差价合约相关的止损安排，则必须提供完整的细节。</p>
</div><p>6. See Rule 2.5(d) of Part A of the Rules.</p>
<div class="lb-trans"><p>6. 请参见规则第 2.5(d) 条。</p>
</div><p>7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.</p>
<div class="lb-trans"><p>7. 如果根据规则第 8 条披露的信息不正确，应在后续披露中尽快更正。该披露应明确说明其更正了之前披露的细节，识别被更正的披露，并提供足够的细节以便读者理解更正的性质。如有任何疑问，应咨询小组。</p>
</div><p>For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.</p>
<div class="lb-trans"><p>有关披露要求的完整细节，请参见规则第 8 条。如有疑问，请咨询小组。</p>
</div><p>References in these notes to &#34;the Rules&#34; are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.</p>
<div class="lb-trans"><p>这些说明中提到的 “规则” 是指 1997 年爱尔兰收购小组法案、2022 年收购规则。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由伦敦证券交易所的新闻服务 RNS 提供。RNS 获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END ITPMZMMZMGRGKZM</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址以确认遵守条款和条件，分析您与本通信中包含的信息的互动，并将此类分析以匿名方式与他人分享，作为我们商业服务的一部分。有关 RNS 和伦敦证券交易所如何使用您提供的个人数据的更多信息，请参见我们的隐私政策。结束 ITPMZMMZMGRGKZM</p>
</div>

REG - Janus Henderson 投资公司 Avadel Pharma plc - 表格 8.3 - Avadel Pharmaceuticals plc